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CONTRIBUTION
What does this work add to what is already known?
Sildenafil has modest short-term effect on the mother's cardiovascular system. It increases 
heart rate, reduces blood pressure and arterial stiffness in pregnancies complicated by 
severe early-onset fetal growth restriction. These changes are consistent with the anticipated 
vasodilatory effect.
What are the clinical implications of this work?
The findings of this study are valuable in view of the scarcity of available data on the effect of 
sildenafil on the maternal hemodynamics. They provide reassurance that any cardiovascular 
changes caused by the administration of sildenafil during pregnancy are modest and appear 
to have no short or long-term clinical impact on the mother.
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ABSTRACT
OBJECTIVES
Fetal growth restriction (FGR) is associated with maternal cardiovascular changes. 
Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide and 
has been proposed to alter maternal hemodynamics, potentially improving placental 
perfusion. Recently, the Dutch trial was stopped prematurely due to excess neonatal 
mortality secondary to pulmonary hypertension.
The main aim of this study was to investigate the effect of sildenafil on maternal 
hemodynamics in pregnancies with severe early-onset FGR.
METHODS
In this UK multicenter, placebo-controlled trial, we randomly assigned 135 women with 
singleton pregnancies and severe early-onset FGR (defined as a combination of estimated 
fetal weight or abdominal circumference below the 10th centile and absent/reversed end 
diastolic flow in the umbilical artery on Doppler velocimetry diagnosed between 22+0-29+6 
weeks’ gestation), to receive either sildenafil 25mg three times daily or placebo until 32+0 
weeks’ gestation or delivery.
The maternal blood pressure (BP), heart rate (HR), augmentation index, pulse wave velocity 
(PWV), cardiac output, stroke volume (SV) and total peripheral resistance were recorded 
before, 1-2 hours after, and 48-72 hours post-randomization, and 24-48 hours postnatally. 
For continuous data, the analysis was performed using repeated measures ANOVA methods 
including terms for time, treatment allocation and their interaction.
RESULTS
Sildenafil increased maternal HR by 4bpm when compared to placebo [5bpm (95%CI: 1, 12) 
vs 1 (-5, 8); P=0.004] and reduced systolic BP by 1mmHg more than placebo [-4mmHg (-9, 
1) vs -3mmHg (-8, 5); P=0.048]. Even after adjusting for maternal BP, sildenafil reduced 
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aortic PWV by 0.6 m/sec more than placebo did [-0.90m/sec (-1.31, -0.51) vs -0.26 (-0.75, 
0.59); P=0.001]. Sildenafil was associated with a non-significant decrease in the SV index [-
5.5m/m2/beat (-11, -0.5) vs 0 (-0.5, 4); P=0.056].
CONCLUSIONS
Sildenafil in a dose of 25 mg three times daily increases HR, reduces BP and reduces 
arterial stiffness in pregnancies complicated by FGR. These changes are modest, consistent 
with the anticipated vasodilatory effect and their clinical impact on the mother and baby, in 
both the short- and long-term, remains uncertain.
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INTRODUCTION
Early-onset fetal growth restriction (FGR), in the absence of genetic abnormalities or 
congenital infection, is usually associated with impaired placentation.1,2 Attempts to develop 
antenatal therapy have yet to prove successful, so currently the only management option is 
preterm delivery with its associated significant risks of neonatal mortality and morbidity.
The commonest clinical indication for sildenafil is erectile dysfunction as it causes relaxation 
of the vascular smooth muscle in the corpus cavernosum that is essential for penile erection. 
This action is mediated through nitric oxide (NO), which activates guanylate cyclase to 
produce cyclic guanosine monophosphate (cGMP), reducing intracellular calcium. Sildenafil 
is a highly selective inhibitor of phosphodiesterase type 5, which is responsible for the 
degradation of cGMP, ultimately enhancing the effects of NO. NO decreases systemic 
vascular resistance (SVR) and blood pressure (BP), while nitrates cause a marked reduction 
in the intensity of early wave reflection in the aorta and improve arterial compliance.3
Despite initial promising results from in vivo animal studies, and in observational and small 
randomized controlled human studies,4-10 sildenafil did not prolong the pregnancy or improve 
pregnancy outcomes in severe early-onset FGR, when tested in an adequately powered 
multicenter randomized controlled trial.11 Recently, the Dutch STRIDER trial was stopped 
prematurely due to excess neonatal mortality secondary to pulmonary hypertension.12 
Therefore, there is ongoing interest in ascertaining the cardiovascular effects of sildenafil in 
pregnancy.
Normal pregnancy is associated with marked cardiovascular changes that might limit the 
additional vasodilator effect of sildenafil on blood vessels which are already maximally 
dilated. In normal pregnancy, the trophoblast produces NO, a potent venous and arterial 
vasodilator. Despite the fact that sildenafil’s effect on the cardiovascular system has been 
investigated in several studies outside pregnancy, little is known about its maternal 
cardiovascular effects in pregnancy. A recent observational study reported a significant 
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increase in maternal cardiac output (CO) and stroke volume (SV) and a decrease in SVR 
after two weeks of NO donor therapy.13 Studies have reported impaired maternal cardiac 
function and increased arterial stiffness and SVR in pregnancies complicated by FGR.14-19 In 
fact, the impaired maternal cardiac output (CO) reported in women who develop 
hypertensive disorders in pregnancy has recently been shown to be present in those 
complicated by FGR, but not in those without FGR.20 Similar changes have been described 
in non-pregnant individuals with disorders associated with endothelial dysfunction, such as 
hypertension, coronary heart disease and heart failure.21-23
Arterial stiffness is a marker of vascular health and is a prognostic marker for cardiovascular 
disease in the general population; both low and high risk.24-27 Both pulse wave velocity 
(PWV), which is a direct measure of arterial stiffness, and augmentation index (AIx), which is 
a surrogate measure of arterial stiffness, can be measured non-invasively in pregnancy. We, 
and others, have demonstrated increas d arterial stiffness (PWV and AIx) before, during and 
after the clinical stage of preeclampsia.28-36 
The aim of this study was to investigate the effect of sildenafil therapy on maternal 
cardiovascular parameters in singleton pregnancies complicated by severe early-onset FGR, 
in a multicenter randomized controlled trial.
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METHODS
Trial design and participants
The study was designed as a cardiovascular sub-study within a multicenter randomized 
controlled trial of sildenafil, prescribed at a dose of 25 mg three times per day, versus the 
placebo equivalent.11 This dosage regimen was based on previous studies.9,37 The inclusion 
criteria were singleton pregnancies between 22+0 and 29+6 weeks of gestation with a 
diagnosis of FGR, where the mothers had agreed to expectant management. FGR was 
defined as a fetus with abdominal circumference (AC) or estimated fetal weight (EFW) below 
the 10th centile using local charts, with absent or reversed end diastolic flow in the umbilical 
artery on Doppler velocimetry. The exclusion criteria included maternal age less than 16 
years, known contraindication or allergy to sildenafil, known or suspected significant 
chromosomal or structural anomaly, reported current cocaine use, or the presence of a 
condition likely to require delivery within 72 hours (such as severe pre-eclampsia).
Ethical approval was given by the North East Research Ethics Committee (14/NE/0011) in 
the United Kingdom. Each participating site provided site specific approval and all 
participants provided written informed consent. The trial was funded by the National Institute 
for Health Research (NIHR) and the Medical Research Council, neither of which had any 
direct involvement in study design, data collection, analysis, interpretation or writing the 
manuscript. The trial was sponsored by the University of Liverpool and Liverpool Women’s 
Hospital. An Independent Safety Data Monitoring Committee (ISDMC) was established to 
review the safety and efficacy data. The protocol was first registered on 31st July 2014, four 
months before the first patient was recruited (ISRCTN39133303).
Treatment allocation and trial procedures
A web-based application was used to allocate treatment arm, with randomization stratified by 
site and gestation. Gestational age was confirmed by first trimester ultrasound assessment 
of crown-rump length. In each case, the diagnosis of severe early-onset FGR was confirmed 
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by a fetal medicine specialist. In addition, a full history, measurements of maternal 
cardiovascular parameters (pulse and BP), fetal biometry and Doppler velocimetry were 
taken, and maternal venepuncture for angiogenic biomarkers was carried out at 
randomization. Randomization lists were pre-generated using randomly permuted blocks of 
size 2 and 4.
All participants had a further assessment of BP and pulse, and a blood sample taken within 
2 hours after receiving their first oral dose. Subsequently, women were followed up within 3-
4 days and at weekly intervals thereafter or earlier when clinically indicated. The rest of 
clinical care was at the discretion of the local fetal medicine experts and included regular 
ultrasound assessment of growth and Doppler blood flow, and antenatal cardiotocography.
Medication was over-encapsulated (Sharp Clinical Services, UK) to ensure that the 
participants, clinicians and pharmacists were blinded to the study drug. All participants 
received oral medication, sildenafil 25mg or placebo, three times a day. The medication was 
dispensed in 10 day supplies with a new supply being provided every week to ensure there 
was no period when medication was missed. Pharmacy logs were used to monitor 
adherence. The treatment was stopped at 32+0 weeks or delivery, whichever came sooner. 
Women were advised of potential side-effects and their family physician was informed by 
letter of trial participation.
Data on pregnancy outcomes were collected prospectively from the clinical maternity notes 
and entered onto an electronic database. Data quality and protocol compliance were 
monitored regularly using both central and on-site monitoring methods.
Outcome measures
The primary efficacy outcome was the time from randomization until delivery, measured in 
days. This outcome was chosen as any safe prolongation of pregnancy is likely to be 
beneficial for the FGR fetus. Secondary outcomes included live birth, fetal and neonatal 
death, birth weight, neonatal morbidity (any intraventricular hemorrhage, oxygen 
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dependency at 28 days or 36 weeks corrected gestational age, necrotizing enterocolitis or 
retinopathy of prematurity), use of surfactant, ventilator dependency, admission to neonatal 
intensive care unit, time to newborn discharge and maternal side-effects.
Maternal cardiovascular assessment
Maternal cardiovascular assessment was performed before randomization, 1-2 hours after 
randomization, 48-72 hours post-randomization, and 24-48 hours postnatally. The 
recordings were made by researchers who had received appropriate training on the use of 
the Arteriograph® and Non-invasive Cardiac Output Monitor (NICOM)®. All measurements 
were performed in a temperature-controlled room (approximately 22C) with participants in 
the semi-recumbent position. The results of the research cardiovascular assessment were 
not given to the women or their doctors and did not influence subsequent management of 
the pregnancies.
Recording of maternal BP and heart rate (HR)
The maternal BP and HR were measured by automated devices (3BTO-A2, Microlife®), 
which were calibrated before and at regular intervals during the study. The women were in 
the semi-recumbent position, their arms supported at the level of the heart, and a small 
(<22cm), normal (22 to 32cm), or large (33 to 42cm) adult cuff used depending on the mid-
arm circumference was applied.38 After resting for 5 minutes, BP was measured in both arms 
simultaneously, and a series of recordings made at one-minute intervals until variations 
between consecutive readings fell within 10 mmHg in systolic and 6 mmHg in diastolic BP in 
both arms.39 When this point of stability was reached, the mean arterial pressure (MAP) of 
each arm was calculated as the average of the last two stable measurements and, as 
recommended, the measurement in the arm with the highest final MAP was taken for 
analysis. The device measured the maternal HR at the same time. The average of the last 
two measurements was recorded.
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Evaluation of the maternal aortic elastic properties and wave reflection indices
Maternal arterial stiffness and wave reflection were assessed using the Arteriograph® 
(TensioMed Ltd., Budapest, Hungary). The parallel, straight-line distance between the 
suprasternal notch and the upper border of the symphysis pubis (Jug - Sy) was determined 
using a caliper as this provides an indirect measure of the aortic length.40 The Arteriograph® 
cuff was then applied on the left arm over the brachial artery for estimation of pulse wave 
velocity (PWV) (m/s) and augmentation index (AIx) (%) and measurement of MAP in mmHg. 
The cuff acts as a sensor and records the early (direct) systolic wave (P1), late (reflected) 
systolic wave (P2) and diastolic waves (P3) secondary to the central pressure changes. The 
Arteriograph® first measures the systolic and diastolic BP oscillometrically. Subsequently, 
the cuff is decompressed and, in a few seconds, inflated, first to the measured diastolic 
pressure and second to a supra-systolic pressure (measured SBP plus 35 mmHg). The 
pressure fluctuations in the brachial art ry at both pressure levels are detected by the cuff 
and the signals transmitted wirelessly to a computer which contains software (version 
1.10.0.1) for analysis. An overview of the cardiovascular parameters recorded in this study is 
provided as supplementary material. 
The AIx was calculated by dividing the pressure difference between the first forward wave 
due to systole and the second reflected wave (P2-P1) by the pulse pressure (PP) [AIx = (P2 
-P1) x 100 / PP] (Figure 1).41 The aortic PWV (PWVAo) was calculated by dividing the 
distance between the suprasternal notch and the upper border of the symphysis pubis in 
metres (Jug – Sy) by the return time, which is the time interval between the onset of the first 
systolic wave and the onset of the second reflected wave in seconds (RT).42
)(2/
)(
sRT
mSyJug
s
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Evaluation of the maternal cardiac output, stroke volume and total peripheral resistance
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The maternal CO, SV and total peripheral resistance (TPR) and their indices (CI, SVI and 
TPRI) were assessed using NICOM® (Cheetah Medical, Portland, OR, USA), a commercially 
available, non-invasive device which utilizes thoracic bioreactance.  Bioreactance technology 
measures the phase shift in voltage across the thorax. The human thorax can be described 
in terms of an electric circuit with a capacitor (C) and a resistor (R); together these create 
thoracic impedance (Zo). The two components of impedance are the amplitude (a) (the 
magnitude of impedance, which is measured in Ohms (Ω)) and phase (phi, Φ) (the direction 
of the impedance, measured in degrees). The pulsatile ejection of blood from the heart 
modifies the value of R and C, leading to an instantaneous change in the amplitude and 
phase of Zo. Phase shifts occur due to pulsatile flow, the overwhelming majority of which 
stems from the aorta. Because the volume of thoracic fluid is relatively static, the NICOM® 
signal is unaffected by thoracic fluid status including in cases of pulmonary edema. The 
phase detector within the NICOM® monitor detects the phase shifts and computes these into 
the NICOM® signal. An explanation of the NICOM® technical aspects and their principals is 
provided as Supplementary material. 
NICOM® is entirely non-invasive and operator independent. The NICOM® system consists of 
a high frequency (75 kHz) sine wave generator and four dual-electrode skin sensors that are 
used to establish electrical contact with the patient. Within each sensor, one electrode is 
used to inject the high-frequency sine wave into the thorax, and the second electrode is used 
by the voltage input amplifier. Two paired skin sensors are placed on the right side of the 
thorax and two on the left. The currents are passed between the outer electrodes of the 
paired skin sensors, whilst the voltages are recorded from the inner pair. The result is a non-
invasive CO measurement signal from each half of the body – these are averaged to 
produce the final CO measurement. The NICOM® system’s signal processing unit 
determines the relative phase shift (Δ Φ) between the input and output signals. The peak 
rate of change of Φ (dΦ/dTmax) is proportional to the peak aortic flow during each heartbeat. 
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The following formula is used to calculate stroke volume: C x VET x dΦ/dTmax, where C is a 
constant of proportionality and ventricular ejection time (VET) is determined from the 
NICOM’s® electrocardiographic signals.
Statistical analysis
The STRIDER UK trial recruited 135 women (70 women received sildenafil and 65 placebo) 
from 18 fetal medicine units in the UK between November 2014 and July 2016. The sample 
size calculation planned to recruit 112 women; this was later increased to 135 women in 
consultation with the ISDMC to account for lower than expected live births. Although the 
power for the primary outcome increased to 94% (post-hoc calculation), this increased 
sample size would still not have adequate power to detect clinically important differences for 
most secondary outcomes and the cardiovascular substudy. The participants’ groups were 
defined for analysis on an intention-to-treat basis. None of the women withdrew their consent 
or were lost to follow-up, so an additional ‘per protocol’ analysis was not performed.
Data are presented as median and interquartile range (IQR) for continuous data and as n 
(%) for categorical variables. Comparison between the study groups (sildenafil vs placebo) 
was by χ2-test or Fisher’s exact test for categorical variables and the Mann–Whitney U-test 
for continuous variables. We analysed the repeat maternal cardiovascular data using 
repeated measures ANOVA methods including terms for time and treatment allocation. The 
maternal PWV values were adjusted for BP, while the AIx was adjusted for maternal HR. P 
values less than 0.05 were considered statistically significant. We performed all analyses 
with the statistical software package, R (version 3.3.3).
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RESULTS
Study population
The STRIDER cardiovascular substudy included 134 women (randomly assigned 69 women 
to sildenafil and 65 women to placebo) who had recording of the maternal BP and HR at 
baseline. One-hundred and twenty nine (Sildenafil=66; Placebo=63) women provided data at 
one hour, 116 women provided data (Sildenafil=62; Placebo=54) 48-72 hours post-
randomization, and 65 women provided data (Sildenafil=31; Placebo-34) postnatally. 
Maternal aortic elastic properties and wave refection indices were performed in 60 women 
(randomly assigned 32 women to sildenafil and 28 women to placebo), while assessment of 
the maternal CO, SV and TPR was performed in 83 women (randomly assigned 44 women 
to sildenafil and 39 women to placebo) (Figure 1). Table 1 presents a comparison between 
the study groups.
Maternal BP and HR
The maternal systolic BP, diastolic BP and HR values at all time points and by treatment 
group are illustrated in Figures 2-4. The maternal systolic BP [131.88 (121.75, 138.63) vs 
133.75 (124.25, 144.50), p<0.001], diastolic BP [83.50 (77.88, 89.19) vs 87 (80.00, 94.25), 
p<0.001] and MAP [97.30 (92.65, 105.73) vs 103.0 (94.15, 110.20), p<0.001] values 
decreased significantly 1-2 hours following the administration of sildenafil. The maternal HR 
increased significantly 1-2 hours following the administration of sildenafil [83.5 (77.5, 93.5) 
vs 79.0 (73.0, 87.0), p<0.001]. When compared with pre-randomization, the maternal 
systolic BP [130.50 (123.50, 142.25) vs 133.75 (124.25, 144.50), p=0.036], diastolic BP 
[85.75 (78.50, 90.50) vs 87 (80, 94.25), p=0.045] values were also significantly lower 48-72 
hours post-randomization. The maternal HR values were also significantly higher 48-72 
hours post-randomization compared to baseline [83.5 (75.1, 92.5) vs 79.0 (73.0, 87.0), 
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p=0.002]. Only the maternal HR values were significantly higher at the postnatal assessment 
compared to pre-randomization [83.0 (78.8, 91.3) vs 79.0 (73.0, 87.0), p=0.001]. The 
maternal systolic BP, diastolic BP and HR values before, 1-2 hours after, 48-72 hours post-
randomization, and postnatally in the study groups (sildenafil and placebo) are shown in 
Supplementary Material. Table 2 shows a comparison of the mean difference in the maternal 
BP and HR between the various time points for the sildenafil and placebo groups. Sildenafil 
increased maternal HR by 4bpm more than placebo did [5bpm (95% CI: 1, 12) vs 1 (-5, 8); 
P=0.004] and reduced systolic BP by 1mmHg more than placebo [-4mmHg (-9, 1) vs -
3mmHg (-8, 5); P=0.048] (Table 2). There were no significant differences among the 
remaining values at different time points between the two study groups (p>0.05).
Maternal PWV and AIx
The maternal PWV adjusted for BP, and AIx adjusted for HR values before, 1-2 hours after, 
48-72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo) 
are illustrated in Figures 5 and 6. One to two hours following administration, sildenafil 
reduced the maternal aortic AIx (AlxAo) adjusted for HR [17.93 (9.06, 28.73) vs 29.34 
(12.02, 50.08), p=0.002] and PWV adjusted for MAP [8.85 (8.04, 10.39) vs 10.25 (8.76, 
11.27), p<0.001]. When compared with pre-randomization, the maternal AlxAo adjusted for 
HR [26.67 (12.41, 45.75) vs 29.34 (12.02, 50.08), p=0.001] and PWV adjusted for MAP [8.59 
(7.91, 9.75) vs 10.25 (8.76, 11.27), p=0.016] values were also significantly lower 48-72 
hours post-randomization. Only the maternal AlxAo adjusted for HR values were significantly 
lower postnatally when compared to pre-randomization [28.25 (14.36, 44.54) vs 29.34 
(12.02, 50.08), p=0.003]. The maternal PWV and AIx values before, 1-2 hours after, and 48-
72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo) are 
shown in Supplementary Material. Table 3 shows a comparison of the mean difference in the 
maternal PWV and AlxAo between the various time points between the sildenafil and 
placebo groups. Even after adjusting for maternal BP, sildenafil reduced aortic PWV by 0.6 
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m/sec more than placebo [-0.90m/sec (-1.31, -0.51) vs -0.26 (-0.75, 0.59); P=0.001]. There 
were no significant differences among the remaining values at different time points between 
the two study groups (p>0.05).
Maternal cardiac function and TPR
The maternal CO, SV and TPR before, 1-2 hours after, 48-72 hours post-randomization, and 
postnatally in the study groups are illustrated in Figures 7-9. Within two hours following 
administration, sildenafil reduced the maternal SV [66.45 (56.40, 82.94) vs 75.95 (67.05, 
84.83), p=0.003] and SVI [41.00 (31.50, 47.00) vs 45.00 (38.00, 51.25), p=0.003]. The 
maternal CO, CI, SV, SVI, TPR and TPRI values before, 1-2 hours after, 48-72 hours post-
randomization, and postnatally in the study groups are shown in Supplementary Material. 
Table 4 shows a comparison of the mean difference in the maternal CO, CI, SV, SVI, TPR 
and TPRI between the various time points for the study groups. Sildenafil was associated 
with a non-significant decrease in the SVI [-5.5m/m2/beat (-11.0, -0.5) vs 0 (-0.5, 4.0); 
P=0.056]. There were no significant differences among the remaining values at different time 
points between the two study groups (p>0.05).
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DISCUSSION
Summary of the study findings
Our results show that sildenafil reduces maternal BP with a compensatory rise in HR. Even 
after adjusting for maternal BP and HR, sildenafil reduces arterial stiffness in pregnant 
women with severe early-onset FGR. However, these effects are mild and short lasting.
Interpretation of the study findings
Our findings of a reduction in BP, increase in HR and decline in arterial stiffness in these 
pregnant women are consistent with the literature in non-pregnant individuals, despite 
different regimens of sildenafil, methods of cardiovascular assessment and time points.43-46
Taking some correction for  p value into account in view of the multiple comparisons, only  a 
slight rise in HR and PWV adjusted for MAP (after 1 - 2 hours) then remain significant. When 
the cardiovascular parameters were compared between the baseline assessment prior to 
randomization and post-randomization, some of the changes we observed at the second 
assessment (within 1-2 hours) were not sustained at the third assessment (48-72 hours). 
This suggests that the cardiovascular effects of sildenafil in these pregnancies may be short-
lived. Other RCTs of sildenafil use in pregnancies complicated by FGR or pre-eclampsia 
assessed the maternal BP 2-3 hours or within 24 hours after randomization.47,48 There was 
no further cardiovascular assessment beyond 24 hours, so their findings could not address 
whether or not the effect of sildenafil on maternal BP is sustained.47,48
Strengths and weaknesses
This is the first RCT which investigates the effect of sildenafil on maternal arterial and 
cardiac function in pregnancies complicated by severe early-onset FGR. The BP device 
used is validated in pregnant women and in pre-eclampsia. The use of a validated device is 
important as pregnancy-induced vascular changes can affect BP measurements, rendering 
commonly available devices inaccurate in pregnancies complicated by hypertensive 
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disorders.49,50 The cardiovascular assessment was performed at several time points, 
enabling us to assess both the short- and long-term effects of sildenafil. Sildenafil was 
associated with significant changes in maternal cardiovascular parameters, but these effects 
were not sustained. All the pregnancies included in this study were complicated by severe 
early-onset FGR, so we avoided the potentially heterogeneous cardiovascular phenotypes in 
early and late FGR or in pregnancies complicated by pre-eclampsia (only 17% of our study 
population had pre-eclampsia).11 However, our results might not be generalizable to 
pregnancies with pre-eclampsia or late-onset FGR.
The main limitation of our study is the relatively small number of participants, meaning that 
the cardiovascular substudy might not have been adequately powered. However, severe 
early-onset FGR is a rare event affecting less than 1% of pregnancies and most of the RCTs 
investigating the effect of sildenafil on cardiovascular parameters included smaller numbers 
of participants than our current study.43-46
The availability of non-invasive methods for assessing maternal hemodynamics has enabled 
researchers to investigate changes in the cardiovascular system in both normal and 
pathological pregnancies. However, most of these devices are not validated in pregnancy, 
as validation against the invasive gold standard is challenging for practical and ethical 
reasons. The devices we used to assess arterial and cardiac function are fully automated, 
thus minimizing intra- and inter-observer variability. The Arteriograph® has been validated 
against invasive and non-invasive methods in non-pregnant populations.41,42,51 Even though 
there are no direct validation studies of the Arteriograph® in pregnancy, it has been used on 
a very large scale in pregnancy research.17,31,52,53 Measurements from the Arteriograph® had 
a highly significant correlation with conventional tonometric and piezo-electric platforms.41 
Similarly, there are no published studies of invasive validation of the NICOM® device in 
pregnant women. However, good agreement between NICOM® and echocardiography has 
been reported, specifically in the third trimester of pregnancy.54 Of note, our study findings 
are consistent with the literature in non-pregnant individuals, despite the use of different 
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methods of cardiovascular assessment.43-46 Therefore, despite the limitations of our study, 
the data provide valuable and novel findings.
Clinical and research implications
Our finding of a reduction in BP is consistent with data from RCTs of the use of sildenafil in 
pregnant women with FGR.48 In a recent RCT which included 35 singleton pregnancies with 
FGR between 24 and 31+6 weeks of gestation randomized to oral sildenafil citrate, 
transdermal nitroglycerin (GTN) or placebo, maternal BP decreased with administration of 
either GTN and sildenafil when recorded 2-3 hours after administration. However, this effect 
was no longer significant when women with pre-eclampsia were excluded from the 
analysis.48
In normal pregnancy, the trophoblast produces nitric oxide (NO), which is a potent venous 
and arterial vasodilator that also inhibits platelet aggregation. In pregnancies complicated by 
pre-eclampsia or IUGR, placental hypoxia and endothelial dysfunction resulting from 
inflammation are associated with decreased release of NO and increased 
phosphodiesterase type 5 (PDE-5) activity4,5. Therefore, NO donors, which are known PDE-
5 inhibitors, have the potential for prevention as well as treatment of IUGR.
Interestingly, our finding of a reduction in BP is also consistent with the data from RCTs of 
the use of sildenafil in pregnant women with pre-eclampsia.48 In a recent RCT which 
included 100 singleton pregnancies with pre-eclampsia between 24 and 33 weeks of 
gestation randomized to 50mg oral sildenafil citrate every 8 hours or placebo, sildenafil 
reduced the maternal BP when recorded 24 hours after randomization, when compared with 
placebo (sildenafil: 100.3±5.6 mm Hg compared with 116.4±5.1 mm Hg, P<0.05; placebo: 
110.6±6.2 mm Hg compared with 114.7±6.5 mm Hg, P=0.21).48 However, recent evidence 
from animal studies suggests that sildenafil might have different effects on BP depending on 
the baseline BP.55 In a recent meta-analysis including 22 animal studies, sildenafil had a 
significant BP lowering effect only in pregnancies complicated by either FGR or pre-
eclampsia (-19 mmHg). The size of the effect was dependent on the baseline BP and there 
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was no effect in the absence of hypertension.55 This might explain the modest effect of 
sildenafil seen in our study, as the majority of women in the STRIDER trial did not have 
hypertension. Of note, none of these RCTs performed detailed maternal cardiovascular 
assessment, so the effect of sildenafil on maternal PWV, AIx, CO, SV and SVR has not 
previously been explored.
The findings of our study are valuable in view of the scarcity of available data on the effect of 
sildenafil on the maternal hemodynamics. They provide reassurance that any cardiovascular 
changes caused by the administration of sildenafil during pregnancy are modest and appear 
to have no short or long-term clinical impact on the mother or baby. However, larger studies 
are needed to ascertain the effect of different doses and frequency of sildenafil 
administration on maternal hemodynamics and in other populations, such as late-onset 
FGR.
Conclusions
Sildenafil increases maternal HR and reduces BP and arterial stiffness in pregnancies 
complicated by severe early-onset FGR. However, these changes are modest and have no 
short- or long-term clinical impact on the mother.
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FIGURE LEGENDS
Figure 1. Study Flow chart.
Figure 2. Maternal brachial systolic blood pressure (BP) values before, 1-2 hours after, and 
48-72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo). 
In the sildenafil group, the maternal systolic BP [131.88 (121.75, 138.63) vs 133.75 (124.25, 
144.50), p<0.001] values decreased significantly 1-2 hours following the administration of 
sildenafil. When compared with pre-randomization, the maternal systolic BP [130.50 (123.50, 
142.25) vs 133.75 (124.25, 144.50), p=0.036], diastolic BP [85.75 (78.50, 90.50) vs 87 (80, 
94.25), p=0.045] values were also significantly lower 48-72 hours post-randomization. The 
maternal systolic BP values were not significantly different in the postnatal period when 
compared with pre-randomization values (p>0.05). * indicates p<0.05 when compared with 
the pre-randomization values. Values in red belong to the sildenafil group, while values in 
blue belong to the placebo group.
Figure 3. Maternal brachial diastolic blood pressure (BP) values before, 1-2 hours after, and 
48-72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo). 
In the sildenafil group, the maternal diastolic BP [83.50 (77.88, 89.19) vs 87 (80.00, 94.25), 
p<0.001] values decreased significantly 1-2 hourd following the administration of sildenafil. 
When compared with pre-randomization, the maternal diastolic BP [85.75 (78.50, 90.50) vs 
87 (80, 94.25), p=0.045] values were also significantly lower 48-72 hours post-
randomization. The maternal diastolic BP were not significantly different in the postnatal 
period when compared with pre-randomization values (p>0.05). * indicates p<0.05 when 
compared with the pre-randomization values. Values in red belong to the sildenafil group, 
while values in blue belong to the placebo group.
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Figure 4. Maternal heart rate (HR) values before, 1-2 hours after, and 48-72 hours post-
randomization, and postnatally in the study groups (sildenafil and placebo). In the sildenafil 
group, the maternal HR increased significantly 1-2 hours following the administration of 
sildenafil [83.5 (77.5, 93.5) vs 79.0 (73.0, 87.0), p<0.001]. The maternal HR values were 
also significantly higher 48-72 hours post-randomization compared to baseline [83.5 (75.1, 
92.5) vs 79.0 (73.0, 87.0), p=0.002]. The maternal HR values were significantly higher at the 
postnatal assessment compared to pre-randomization [83.0 (78.8, 91.3) vs 79.0 (73.0, 87.0), 
p=0.001]. In the placebco group, the maternal HR values were significantly higher at the 
postnatal assessment compared to pre-randomization [87 (70, 94.5) vs 76 (70, 85.5), 
p=0.025]. * indicates p<0.05 when compared with the pre-randomization values. Values in 
red belong to the sildenafil group, while values in blue belong to the placebo group.
Figure 5. Maternal pulse wave velocity (PWV) values adjusted for blood pressure (BP) 
before, 1-2 hours after, and 48-72 hours post-randomization, and postnatally in the study 
groups (sildenafil and placebo). Within 1-2 hours following administration, sildenafil reduced 
the maternal PWV adjusted for MAP [8.85 (8.04, 10.39) vs 10.25 (8.76, 11.27), p<0.001]. 
When compared with pre-randomization, the maternal PWV adjusted for MAP [8.59 (7.91, 
9.75) vs 10.25 (8.76, 11.27), p=0.016] values were also significantly lower 48-72 hours post-
randomization. The values were not significantly different postnatally when compared to pre-
randomization (p>0.05). * indicates p<0.05 when compared with the pre-randomization 
values. Values in red belong to the sildenafil group, while values in blue belong to the 
placebo group.
Figure 6. Maternal aortic augmentation index (AIxAo) values adjusted for heart rate before, 
1-2 hours after, and 48-72 hours post-randomization, and postnatally in the study groups 
(sildenafil and placebo). One to two hours following administration, sildenafil reduced the 
maternal aortic AIx (AlxAo) adjusted for HR [17.93 (9.06, 28.73) vs 29.34 (12.02, 50.08), 
p=0.002]. When compared with pre-randomization, the maternal AlxAo adjusted for HR 
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[26.67 (12.41, 45.75) vs 29.34 (12.02, 50.08), p=0.001] values were also significantly lower 
48-72 hours post-randomization. The maternal AlxAo adjusted for HR values were 
significantly lower postnatally when compared to pre-randomization [28.25 (14.36, 44.54) vs 
29.34 (12.02, 50.08), p=0.003]. * indicates p<0.05 when compared with the pre-
randomization values. Values in red belong to the sildenafil group, while values in blue 
belong to the placebo group.
Figure 7. Maternal cardiac output (CO) values before, one hour after, and 48-72 hours post-
randomization, and postnatally in the study groups (sildenafil and placebo). When compared 
with pre-randomization, the maternal CO values were not significantly different at 1-2 hours 
post-randomization, 48-72 hours post-randomization, or postnatally (p>0.05 for all). 
Figure 8. Maternal stroke volume values before, one hour after, and 48-72 hours post-
randomization, and postnatally in the study groups (sildenafil and placebo). One to two hours 
following administration, sildenafil reduced the maternal SV [66.45 (56.40, 82.94) vs 75.95 
(67.05, 84.83), p=0.003]. When compared with pre-randomization, the maternal SV values 
were not significantly different at 48-72 hours post-randomization or postnatally (p>0.05 for 
all). * indicates p<0.05 when compared with the pre-randomization values. Values in red 
belong to the sildenafil group, while values in blue belong to the placebo group.
Figure 9. Maternal total peripheral resistance values (TPR) before, 1-2 hours after, and 48-
72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo). 
When compared with pre-randomization, the maternal TPR values were not significantly 
different at 1-2 hours post-randomization, 48-72 hours post-randomization, or postnatally 
(p>0.05 for all).
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Table 1. Baseline characteristics
Covariate Level
Placebo
(n=65)
Sildenafil
(n=69)
Total
(n=134)
Gestation at Delivery in weeks median (IQR) 28.43 (27.29, 30.14) 28.14 (26.71, 29.71) 28.29 (26.86, 29.71)
Maternal age in years median (IQR) 33 (28, 36) 29 (26, 34) 30 (27, 35)
Maternal weight in kilograms median (IQR) 70 (60, 82) 66 (58, 80) 69.5 (60, 82)
Maternal height in cm median (IQR) 163 (158, 166) 163 (158, 167) 163 (158, 166.75)
Maternal BMI (kg/m2) median (IQR) 26.49 (22.72, 31.22) 24.8 (22.86, 31.23) 25.42 (22.785, 31.22)
African 7 (54%) 6 (46%) 13
Asian - Other 0 (0%) 1 (100%) 1
Caribbean 2 (50%) 2 (50%) 4
Chinese 1 (100%) 0 (0%) 1
Indian 3 (43%) 4 (57%) 7
Latin American/Hispanic 0 (0%) 1 (100%) 1
Other 1 (33%) 2 (67%) 3
Ethnicity
Pakistani 8 (57%) 6 (43%) 14
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Covariate Level
Placebo
(n=65)
Sildenafil
(n=69)
Total
(n=134)
White - British 35 (45%) 43 (55%) 78
White - European 5 (71%) 2 (29%) 7
White - Other 2 (100%) 0 (0%) 2
White and Asian 0 (0%) 1 (100%) 1
White and Black African 0 (0%) 1 (100%) 1
White and Black Caribbean 1 (100%) 0 (0%) 1
No 42 (42%) 58 (58%) 100
Gestational Hypertension
Yes 23 (68%) 11 (32%) 34
No 54 (49%) 56 (51%) 110
Pre-eclampsia
Yes 11 (46%) 13 (54%) 24
No 62 (48%) 67 (52%) 129
Gestational Diabetes
Yes 3 (60%) 2 (40%) 5
Current smoker 2 (15%) 11 (85%) 13
Smoking Status
Non-smoker at conception 57 (53%) 51 (47%) 108
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Covariate Level
Placebo
(n=65)
Sildenafil
(n=69)
Total
(n=134)
Stopped after 15+0 weeks 3 (60%) 2 (40%) 5
Stopped by 15+0 weeks 3 (38%) 5 (62%) 8
Estimated fetal weight median (IQR) 436 (326, 594) 448 (352, 616.75) 444 (344, 613)
Gestation at recruitment in weeks median (IQR)
25.571 (24.143, 
27.429)
25.143 (24, 27.571) 25.357 (24, 27.536)
No 40 (53%) 35 (47%) 75
Previous pregnancy
Yes 25 (42%) 34 (58%) 59
> 500 21 (44%) 27 (56%) 48
Birthweight in grams
≤ 500 36 (52%) 33 (48%) 69
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Table 2. Comparison of the mean difference in the maternal blood pressure (BP) and heart rate (HR) between the various time points for the 
sildenafil and placebo groups.
Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Pre vs Post Randomization 
(1 - 2hr)
Maternal right arm systolic BP (mmHg) -2.00 (-8.75, 4.50) -5.50 (-10.50, 4.38) 0.086
Maternal left arm systolic BP (mmHg) -2.50 (-8.50, 6.50) -3.00 (-8.25, 1.50) 0.082
Maternal right arm diastolic BP (mmHg) -1.50 (-6.25, 3.50) -4.50 (-8.88, 1.00) 0.029
Maternal left arm diastolic BP (mmHg) -2.00 (-6.75, 3.00) -4.00 (-9.25, -1.00) 0.192
Maternal right arm MAP (mmHg) -1.80 (-6.63, 3.08) -3.85 (-9.28, 1.06) 0.028
Maternal left arm MAP (mmHg) -1.65 (-6.65, 3.00) -3.70 (-7.85, 0) 0.125
Maternal HR (bpm) 1.25 (-5.38, 7.88) 5.00 (1.00, 12.00) 0.004
Maternal average systolic BP -2.75 (-7.50, 5.25) -4.13 (-9.94, 1.44) 0.048
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Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Maternal average diastolic BP -1.50 (-5.63, 2.38) -4.75 (-8.56, -0.31) 0.089
Pre vs Post Randomization 
(48 - 72hr)
Maternal average (between the 2 readings) Right arm 
systolic BP (mmHg)
-2.00 (-10.50, 3.38) -3.25 (-8.88, 2.88) 0.602
Maternal average (between the 2 readings) Left arm 
systolic BP (mmHg)
-0.50 (-8.25, 9.50) -4.00 (-7.25, 4.00) 0.670
Maternal average (between the 2 readings) Right arm 
diastolic BP (mmHg)
-0.75 (-6.50, 6.25) -2.25 (-5.88, 1.50) 0.714
Maternal average (between the 2 readings) Left arm 
diastolic BP (mmHg)
1.50 (-7.00, 5.38) -2.50 (-6.75, 4.25) 0.370
Maternal average (between the 2 readings) Right arm 
MAP (mmHg)
-1.00 (-8.00, 5.16) -3.25 (-6.35, 3.10) 0.991
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Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Maternal average (between the 2 readings) Left arm 
MAP (mmHg)
0.33 (-7.35, 6.03) -1.70 (-6.78, 3.08) 0.344
Maternal HR (bpm) 0.50 (-5.00, 6.50) 5.00 (-1.38, 10.38) 0.13
Maternal average systolic BP -1.63 (-8.63, 5.94) -3.00 (-8.75, 5.25) 0.961
Maternal average diastolic BP -0.5.00 (-5.50, 5.69) -2.00 (-5.75, 3.25) 0.332
Pre vs Postnatal Maternal average (between the 2 readings) Right arm 
systolic BP (mmHg)
-2.75 (-13.00, 8.25) -2.50 (-18.25, 2.75) 0.217
Maternal average (between the 2 readings) Left arm 
systolic BP (mmHg)
-1.50 (-11.00, 6.50) 0 (-12.50, 6.50) 0.444
Maternal average (between the 2 readings) Right arm 
diastolic BP (mmHg)
0.25 (-7.88, 7.50) -2.50 (-10.75, 5.50) 0.496
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Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Maternal average (between the 2 readings) Left arm 
diastolic BP (mmHg)
-1.00 (-8.50, 10.50) -2.00 (-13.00, 4.50) 0.199
Maternal average (between the 2 readings) Right arm 
mean arterial pressure (MAP) (mmHg)
-1.08 (-9.85, 7.30) -1.50 (-14.10, 3.75) 0.337
Maternal average (between the 2 readings) Left arm 
MAP (mmHg)
-1.85 (-9.15, 8.00) -1.15 (-15.65, 5.00) 0.176
Maternal heart rate (bpm) 6.00 (-1.00, 12.00) 8.50 (1.25, 12.00) 0.506
Maternal average systolic BP -0.50 (-10.88, 8.06) -1.50 (-13.25, 3.00) 0.238
Maternal average diastolic BP 0.75 (-6.94, 8.81) -2.50 (-9.75, 5.25) 0.194
Post Randomization (48hr 
– 72hr) vs Postnatal
Maternal average (between the 2 readings) Right arm 
systolic BP (mmHg)
-0.75 (-6.13, 5.88) -4.25 (-13.25, 8.38) 0.615
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Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Maternal average (between the 2 readings) Left arm 
systolic BP (mmHg)
-0.50 (-9.00, 4.75) 0.75 (-10.50, 7.50) 0.816
Maternal average (between the 2 readings) Right arm 
diastolic BP (mmHg)
2.75 (-11.63, 6.50) 0.75 (-7.25, 7.50) 0.611
Maternal average (between the 2 readings) Left arm 
diastolic BP (mmHg)
2.50 (-4.25, 5.75) 1.50 (-10.63, 6.00) 0.582
Maternal average (between the 2 readings) Right arm 
MAP (mmHg)
0.90 (-9.28, 6.13) 0 (-9.59, 8.76) 0.915
Maternal average (between the 2 readings) Left arm 
MAP (mmHg)
0.85 (-7.68, 4.88) 1.50 (-10.54, 3.89) 0.643
Maternal HR (bpm) 4.75 (-3.25, 19.25) 1.50 (-6.88, 6.75) 0.241
Maternal average systolic BP -1.38 (-7.00, 6.19) -2.25 (-11.19, 8.50) 0.686
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Time Points
Factor Placebo (n=62) Sildenafil (n=65)
P 
value
Maternal average diastolic BP 4.25 (-8.94, 7.31) 1.88 (-7.38, 5.38) 0.971
Page 39 of 88
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
1
Table 3. Comparison of the mean difference in the maternal aortic augmentation index (AIxAo) and pulse wave velocity (PWV) between the 
various time points for the sildenafil and placebo groups.
Time Point Factor Placebo (n=28) Sildenafil (n=30) P value
Pre vs Post Randomization (1 - 2hr) AlxAo (%) -4.50 (-10.28, 2.93) -5.85 (-17.10, 2.23) 0.937
Aortic PWV (m/s) 0.25 (-0.37, 0.90) -0.05 (-0.55, 0.83) 0.565
AlxAo adjusted for heart rate (%) -6.03 (-15.52, 3.45) -10.21 (-27.55, -2.86) 0.516
Aortic PWV (m/s) adjusted for MAP -0.26 (-0.75, 0.59) -0.90 (-1.31, -0.51) 0.001
Factor Placebo (n=21) Sildenafil (n=27) P value
Pre vs Post Randomization (48 - 72hr) AlxAo (%) -4.20 (-8.53, 1.00) -1.00 (-10.20, 4.70) 0.599
Aortic PWV (m/s) 0 (-0.65, 0.78) -0.21 (-1.20, 0.30) 0.538
AlxAo adjusted for heart rate (%) 0 (-3.22, 1.87) -1.20 (-3.08, -0.41) 0.269
Aortic PWV (m/s) adjusted for MAP -0.45 (-2.23, 1.55) -0.83 (-1.96, 0.20) 0.489
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Time Point Factor Placebo (n=28) Sildenafil (n=30) P value
Factor Placebo (n=12) Sildenafil (n=12) P value
Pre vs Postnatal AlxAo (%) 3.30 (-2.00, 18.71) 7.30 (-15.90, 10.70) 0.231
Aortic PWV (m/s) 0.10 (-1.00, 1.10) 0.50 (-0.30, 1.30) 0.800
AlxAo adjusted for heart rate (%) -0.32 (-0.91, 0.91) -1.25 (-4.73, -0.58) 0.189
Aortic PWV (m/s) adjusted for MAP 0.01 (-1.71, 1.29) 0.31 (-0.61, 0.58) 0.793
Factor Placebo (n=7) Sildenafil (n=12) P value
Post Randomization (48hr – 72hr) vs Postnatal AlxAo (%) 4.20 (-11.10, 16.10) 6.00 (5.77, 19.30) 0.676
Aortic PWV (m/s) 1.00 (0.20, 1.70) -0.60 (-1.30, 1.02) 0.508
AlxAo adjusted for heart rate (%) -0.70 (-2.55, -0.11) 0 (-0.33, 1.08) 0.771
Aortic PWV (m/s) adjusted for MAP 0.43 (-0.67, 1.86) -0.49 (-1.32, 1.76) 0.405
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Table 4. Comparison of the mean difference in the maternal cardiac function and total peripheral resistance between the various time points for 
the sildenafil and placebo groups.
Time Point Factor Placebo (n=36) Sildenafil (n=42) P value
Pre vs Post 
Randomization (1 - 
2hr)
Cardiac Output (CO) (L/min) 0.20 (-0.50, 0.90) 0 (-0.75, 0.58) 0.467
Cardiac Index (CI) 0.05 (-0.30, 0.50) 0.10 (-0.48, 0.20) 0.226
Heart Rate (HR) 3.00 (-2.00, 8.00) 8.00 (2.50, 14.00) 0.025
Stroke volume (SV) (ml) 0.40 (-7.20, 8.10) -8.15 (-14.68, 0.43) 0.855
Stroke volume index (SVI) 0 (-5.00, 4.00) -5.50 (-11.00, -0.50) 0.056
Total peripheral resistance (TPR) -56.00 (-280.00, 108.00) -19.50 (-154.25, 134.00) 0.533
Total peripheral resistance index (TPRI) -127.00 (-550.00, 211.00) -38.50 (-288.25, 239.25) 0.270
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Time Point Factor Placebo (n=36) Sildenafil (n=42) P value
Factor Placebo (n=31) Sildenafil (n=39) P value
Pre vs Post 
Randomization (48 - 
72hr)
Cardiac Output (CO) (L/min) 0.30 (-0.30, 1.45) 0 (-0.55, 0.45) 0.232
Cardiac Index (CI) 0.20 (-0.20, 0.90) 0 (-0.30, 0.15) 0.103
Heart Rate (HR) 1.0 (-5.0, 7.5) 8.0 (-1.5, 12.5) 0.443
Stroke volume (SV) (ml) 9.30 (-3.95, 14.65) -1.60 (-13.30, 8.20) 0.581
Stroke volume index (SVI) 3.50 (-2.00, 8.25) -1.00 (-8.50, 4.00) 0.041
Total peripheral resistance (TPR) -133.50 (-366.00, 149.00) -36.00 (-199.50, 102.50) 0.073
Total peripheral resistance index (TPRI) -263.00 (-690.00, 302.00) -57.00 (-373.50, 170.00) 0.117
Factor Placebo (N=18) Sildenafil (N=18) P value
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Time Point Factor Placebo (n=36) Sildenafil (n=42) P value
Pre vs Postnatal CO (L/min) 0.55 (-0.38, 1.63) 0.35 (0, 1.05) 0.636
CI 0.30 (-0.18, 0.95) 0.10 (0, 0.70) 0.626
HR 5.0 (1.5, 13.5) 13.0 (2.5, 15.0) 0.175
SV (ml) -4.9 (-18.98, 8.00) -8.10 (-13.23, 2.60) 0.381
SVI -0.50 (-5.75, 4.75) -4.00 (-6.00, 6.00) 0.252
TPR -2.50 (-235.50, 233.75) -43.00 (-145.00, 81.25) 0.557
TPRI -2.50 (-425.25, 379.25) -65.00 (-448.50, 133.75) 0.534
Factor Placebo (n=14) Sildenafil (n=17) P value
Post Randomization 
(48hr – 72hr) vs 
Postnatal
CO (L/min) 0.10 (-0.73, 0.85) 0.10 (-1.10, 1.70) 0.861
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Time Point Factor Placebo (n=36) Sildenafil (n=42) P value
CI -0.05 (-0.40, 0.48) 0 (-0.70, 0.90) 0.734
HR 7.00 (0.25, 12.50) 4.00 (-3.00, 11.00) 0.169
SV (ml) -14.20 (-24.50, 0.70) -6.20 (-14.70, 12.60) 0.056
SVI -2.50 (-7.75, 2.50) -3.00 (-8.00, 7.00) 0.365
TPR -58.00 (-308.25, 326.25) -46.00 (-174.00, 275.00) 0.517
TPRI -50.00 (-630.50, 509.25) -96.00 (-333.00, 498.00) 0.596
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Figure 2. Maternal brachial systolic blood pressure (BP) values before, 1-2 hours after, and 48-72 hours 
post-randomization, and postnatally in the study groups (sildenafil and placebo). In the sildenafil group, the 
maternal systolic BP [131.88 (121.75, 138.63) vs 133.75 (124.25, 144.50), p<0.001] values decreased 
significantly 1-2 hours following the administration of sildenafil. When compared with pre-randomization, the 
maternal systolic BP [130.50 (123.50, 142.25) vs 133.75 (124.25, 144.50), p=0.036], diastolic BP [85.75 
(78.50, 90.50) vs 87 (80, 94.25), p=0.045] values were also significantly lower 48-72 hours post-
randomization. The maternal systolic BP values were not significantly different in the postnatal period when 
compared with pre-randomization values (p>0.05). * indicates p<0.05 when compared with the pre-
randomization values. Values in red belong to the sildenafil group, while values in blue belong to the placebo 
group. 
338x190mm (96 x 96 DPI) 
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Figure 3. Maternal brachial diastolic blood pressure (BP) values before, 1-2 hours after, and 48-72 hours 
post-randomization, and postnatally in the study groups (sildenafil and placebo). In the sildenafil group, the 
maternal diastolic BP [83.50 (77.88, 89.19) vs 87 (80.00, 94.25), p<0.001] values decreased significantly 
1-2 hourd following the administration of sildenafil. When compared with pre-randomization, the maternal 
diastolic BP [85.75 (78.50, 90.50) vs 87 (80, 94.25), p=0.045] values were also significantly lower 48-72 
hours post-randomization. The maternal diastolic BP were not significantly different in the postnatal period 
when compared with pre-randomization values (p>0.05). * indicates p<0.05 when compared with the pre-
randomization values. Values in red belong to the sildenafil group, while values in blue belong to the placebo 
group. 
338x190mm (96 x 96 DPI) 
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Figure 4. Maternal heart rate (HR) values before, 1-2 hours after, and 48-72 hours post-randomization, and 
postnatally in the study groups (sildenafil and placebo). In the sildenafil group, the maternal HR increased 
significantly 1-2 hours following the administration of sildenafil [83.5 (77.5, 93.5) vs 79.0 (73.0, 87.0), 
p<0.001]. The maternal HR values were also significantly higher 48-72 hours post-randomization compared 
to baseline [83.5 (75.1, 92.5) vs 79.0 (73.0, 87.0), p=0.002]. The maternal HR values were significantly 
higher at the postnatal assessment compared to pre-randomization [83.0 (78.8, 91.3) vs 79.0 (73.0, 87.0), 
p=0.001]. In the placebco group, the maternal HR values were significantly higher at the postnatal 
assessment compared to pre-randomization [87 (70, 94.5) vs 76 (70, 85.5), p=0.025]. * indicates p<0.05 
when compared with the pre-randomization values. Values in red belong to the sildenafil group, while values 
in blue belong to the placebo group. 
338x190mm (96 x 96 DPI) 
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Figure 5. Maternal pulse wave velocity (PWV) values adjusted for blood pressure (BP) before, 1-2 hours 
after, and 48-72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo). 
Within 1-2 hours following administration, sildenafil reduced the maternal PWV adjusted for MAP [8.85 
(8.04, 10.39) vs 10.25 (8.76, 11.27), p<0.001]. When compared with pre-randomization, the maternal PWV 
adjusted for MAP [8.59 (7.91, 9.75) vs 10.25 (8.76, 11.27), p=0.016] values were also significantly lower 
48-72 hours post-randomization. The values were not significantly different postnatally when compared to 
pre-randomization (p>0.05). * indicates p<0.05 when compared with the pre-randomization values. Values 
in red belong to the sildenafil group, while values in blue belong to the placebo group. 
338x190mm (96 x 96 DPI) 
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Figure 6. Maternal aortic augmentation index (AIxAo) values adjusted for heart rate before, 1-2 hours after, 
and 48-72 hours post-randomization, and postnatally in the study groups (sildenafil and placebo). One to 
two hours following administration, sildenafil reduced the maternal aortic AIx (AlxAo) adjusted for HR [17.93 
(9.06, 28.73) vs 29.34 (12.02, 50.08), p=0.002]. When compared with pre-randomization, the maternal 
AlxAo adjusted for HR [26.67 (12.41, 45.75) vs 29.34 (12.02, 50.08), p=0.001] values were also 
significantly lower 48-72 hours post-randomization. The maternal AlxAo adjusted for HR values were 
significantly lower postnatally when compared to pre-randomization [28.25 (14.36, 44.54) vs 29.34 (12.02, 
50.08), p=0.003]. * indicates p<0.05 when compared with the pre-randomization values. Values in red 
belong to the sildenafil group, while values in blue belong to the placebo group. 
338x190mm (96 x 96 DPI) 
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Figure 7. Maternal cardiac output (CO) values before, one hour after, and 48-72 hours post-randomization, 
and postnatally in the study groups (sildenafil and placebo). When compared with pre-randomization, the 
maternal CO values were not significantly different at 1-2 hours post-randomization, 48-72 hours post-
randomization, or postnatally (p>0.05 for all). 
338x190mm (96 x 96 DPI) 
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Figure 8. Maternal stroke volume values before, one hour after, and 48-72 hours post-randomization, and 
postnatally in the study groups (sildenafil and placebo). One to two hours following administration, sildenafil 
reduced the maternal SV [66.45 (56.40, 82.94) vs 75.95 (67.05, 84.83), p=0.003]. When compared with 
pre-randomization, the maternal SV values were not significantly different at 48-72 hours post-
randomization or postnatally (p>0.05 for all). * indicates p<0.05 when compared with the pre-
randomization values. Values in red belong to the sildenafil group, while values in blue belong to the placebo 
group. 
338x190mm (96 x 96 DPI) 
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Figure 9. Maternal total peripheral resistance values (TPR) before, 1-2 hours after, and 48-72 hours post-
randomization, and postnatally in the study groups (sildenafil and placebo). When compared with pre-
randomization, the maternal TPR values were not significantly different at 1-2 hours post-randomization, 48-
72 hours post-randomization, or postnatally (p>0.05 for all). 
338x190mm (96 x 96 DPI) 
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Supplementary material
1. Maternal blood pressure (BP) and heart rate (HR)
1.1 Sildenafil Group
1.1.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre-randomization 
(n=69)
Post-randomization (1 
- 2h)
(n=65)
P value
Maternal average (between 
the 2 readings) Right arm 
systolic BP (mmHg)
134 (124, 146) 132.5 (120.25, 141) 0.001
Maternal average (between 
the 2 readings) Left arm 
systolic BP (mmHg)
135 (122.5, 142) 128 (122.25, 138.25) 0.002
Maternal average (between 
the 2 readings) Right arm 
diastolic BP (mmHg)
86 (79, 94) 84 (77.5, 89.25) <0.001
Maternal average (between 
the 2 readings) Left arm 
diastolic BP (mmHg)
88 (79.5, 94) 81.5 (77.5, 89.5) 0.105
Maternal average (between 
the 2 readings) Right arm 
MAP (mmHg)
101.65 (94.5, 111.35) 99.575 (92.31, 105.84) <0.001
Maternal average (between 103 (94.15, 110.2) 97.3 (92.65, 105.73) <0.001
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Factor
Pre-randomization 
(n=69)
Post-randomization (1 
- 2h)
(n=65)
P value
the 2 readings) Left arm 
MAP (mmHg)
Maternal HR (bpm) 79 (73, 87) 83.5 (77.5, 93.5) <0.001
Maternal average systolic 
BP (mmHg)
133.75 (124.25, 144.5)
131.88 (121.75, 
138.63)
<0.001
Maternal average diastolic 
BP (mmHg)
87 (80, 94.25) 83.5 (77.875, 89.188) <0.001
1.1.2 Pre-randomization vs Post-randomization (48 – 72hours)
Factor
Pre-randomization 
(n=69)
Post-randomization 
(48 - 72h)
(n=61)
P 
value
Maternal average (between the 2 
readings) Right arm systolic BP 
(mmHg)
134 (124, 146)
132.75 (124.125, 
143.25)
0.035
Maternal average (between the 2 
readings) Left arm systolic BP 
(mmHg)
135 (122.5, 142) 131 (124, 141) 0.143
Maternal average (between the 2 
readings) Right arm diastolic BP 
86 (79, 94) 85.5 (78.25, 91) 0.056
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Factor
Pre-randomization 
(n=69)
Post-randomization 
(48 - 72h)
(n=61)
P 
value
(mmHg)
Maternal average (between the 2 
readings) Left arm diastolic BP 
(mmHg)
88 (79.5, 94) 87 (77.5, 90.25) 0.146
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
101.65 (94.5, 
111.35)
99.6 (93.163, 108.65) 0.026
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
103 (94.15, 110.2)
101 (92.175, 
108.325)
0.074
Maternal HR (bpm) 79 (73, 87) 83.5 (75.125, 92.5) 0.002
Maternal average systolic BP 
(mmHg)
133.75 (124.25, 
144.5)
130.5 (123.5, 142.25) 0.036
Maternal average diastolic BP 
(mmHg)
87 (80, 94.25) 85.75 (78.5, 90.5) 0.045
1.1.3 Pre-randomization vs Postnatal
Factor
Pre-randomization 
(n=69)
Postnatal 
(n=29)
P 
value
Maternal average (between the 2 
readings) Right arm systolic BP (mmHg)
134 (124, 146)
131.5 (120, 
140.25)
0.063
Maternal average (between the 2 135 (122.5, 142) 130.5 (120.5, 0.269
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Factor
Pre-randomization 
(n=69)
Postnatal 
(n=29)
P 
value
readings) Left arm systolic BP (mmHg) 138)
Maternal average (between the 2 
readings) Right arm diastolic BP (mmHg)
86 (79, 94)
83.5 (76.25, 
90.25)
0.285
Maternal average (between the 2 
readings) Left arm diastolic BP (mmHg)
88 (79.5, 94) 84 (74.5, 90.5) 0.115
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
101.65 (94.5, 
111.35)
98.7 (93, 
107.58)
0.176
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
103 (94.15, 110.2)
96.5 (91.5, 
107.5)
0.106
Maternal heart rate (bpm) 79 (73, 87)
83 (78.75, 
91.25)
0.001
Maternal average systolic BP (mmHg)
133.75 (124.25, 
144.5)
131.25 (120.5, 
139.25)
0.139
Maternal average diastolic BP (mmHg) 87 (80, 94.25)
82 (76.25, 
90.75)
0.173
1.1.4 Post-randomization (48 - 72H) vs Postnatal
Factor
Post-randomization 
(48 - 72h)
(n=61)
Postnatal 
(n=29)
P 
value
Maternal average (between the 2 132.75 (124.125, 131.5 (120, 0.43
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Factor
Post-randomization 
(48 - 72h)
(n=61)
Postnatal 
(n=29)
P 
value
readings) Right arm systolic BP 
(mmHg)
143.25) 140.25)
Maternal average (between the 2 
readings) Left arm systolic BP (mmHg)
131 (124, 141)
130.5 (120.5, 
138)
0.716
Maternal average (between the 2 
readings) Right arm diastolic BP 
(mmHg)
85.5 (78.25, 91)
83.5 (76.25, 
90.25)
1
Maternal average (between the 2 
readings) Left arm diastolic BP (mmHg)
87 (77.5, 90.25) 84 (74.5, 90.5) 0.715
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
99.6 (93.163, 108.65)
98.7 (93, 
107.58)
0.688
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
101 (92.175, 108.33)
96.5 (91.5, 
107.5)
0.624
Maternal HR (bpm) 83.5 (75.125, 92.5)
83 (78.75, 
91.25)
0.871
Maternal average systolic BP 130.5 (123.5, 142.25)
131.25 (120.5, 
139.25)
0.632
Maternal average diastolic BP 85.75 (78.5, 90.5)
82 (76.25, 
90.75)
0.936
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1.2 Placebo Group
1.2.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre-randomization 
(n=65)
Post-randomization 
(1 - 2hour)
(n=62)
P 
value
Maternal average (between the 2 
readings) Right arm systolic BP 
(mmHg)
133 (122, 146) 130.5 (119.75, 141) 0.166
Maternal average (between the 2 
readings) Left arm systolic BP 
(mmHg)
133.5 (120.5, 
142.5)
129 (122.25, 139) 0.232
Maternal average (between the 2 
readings) Right arm diastolic BP 
(mmHg)
84.5 (76.5, 94.5) 85 (78.75, 91.25) 0.196
Maternal average (between the 2 
readings) Left arm diastolic BP 
(mmHg)
87 (78, 93.5) 84.5 (78.5, 91.5) 0.049
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
101.35 (91.15, 
110.15)
100.65 (92.58, 
107.95)
0.19
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
102.3 (92.5, 
109.65)
99.5 (93.18, 108.18) 0.08
Maternal HR (bpm) 76 (70, 85.5) 77 (70.125, 85.875) 0.347
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Factor
Pre-randomization 
(n=65)
Post-randomization 
(1 - 2hour)
(n=62)
P 
value
Maternal average systolic BP 
(mmHg)
133.75 (122, 
144.75)
129.75 (121.63, 
139.75)
0.244
Maternal average diastolic BP 
(mmHg)
85 (77, 93.5) 84 (78.13, 91.5) 0.076
1.2.2 Pre-randomization vs Post-randomization (48 - 72H)
Factor
Pre-randomization 
(n=65)
Post-randomization 
(48 - 72h)
(n=53)
P 
value
Maternal average (between the 2 
readings) Right arm systolic BP 
(mmHg)
133 (122, 146)
131.5 (121.63, 
141.38)
0.117
Maternal average (between the 2 
readings) Left arm systolic BP 
(mmHg)
133.5 (120.5, 142.5) 132.5 (122.5, 140.38) 0.89
Maternal average (between the 2 
readings) Right arm diastolic BP 
(mmHg)
84.5 (76.5, 94.5) 86.5 (78.625, 92) 0.74
Maternal average (between the 2 
readings) Left arm diastolic BP 
87 (78, 93.5) 87.75 (79.375, 93) 0.853
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Factor
Pre-randomization 
(n=65)
Post-randomization 
(48 - 72h)
(n=53)
P 
value
(mmHg)
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
101.35 (91.15, 
110.15)
101.18 (92.35, 
108.31)
0.355
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
102.3 (92.5, 109.65) 103.4 (94.6, 109.23) 1
Maternal HR (bpm) 76 (70, 85.5) 79.5 (72.5, 84) 0.452
Maternal average systolic BP 
(mmHg)
133.75 (122, 
144.75)
131.63 (121.19, 141) 0.408
Maternal average diastolic BP 
(mmHg)
85 (77, 93.5) 86.38 (80, 92) 0.676
1.2.3 Pre-randomization vs Postnatal
Factor
Pre-randomization 
(n=65)
Postnatal
(n=31)
P 
value
Maternal average (between the 2 
readings) Right arm systolic BP (mmHg)
133 (122, 146)
128 (119.5, 
136.875)
0.407
Maternal average (between the 2 
readings) Left arm systolic BP (mmHg)
133.5 (120.5, 142.5)
130.5 (122.5, 
136.5)
0.447
Maternal average (between the 2 
readings) Right arm diastolic BP 
84.5 (76.5, 94.5) 83 (78.75, 90.38) 0.959
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Factor
Pre-randomization 
(n=65)
Postnatal
(n=31)
P 
value
(mmHg)
Maternal average (between the 2 
readings) Left arm diastolic BP (mmHg)
87 (78, 93.5) 84.5 (77, 91) 0.978
Maternal average (between the 2 
readings) Right arm MAP (mmHg)
101.35 (91.15, 
110.15)
98.925 (93.48, 
105.78)
0.688
Maternal average (between the 2 
readings) Left arm MAP (mmHg)
102.3 (92.5, 109.65)
99.8 (92.15, 
106.85)
0.728
Maternal HR (bpm) 76 (70, 85.5) 87 (70, 94.5) 0.025
Maternal average systolic BP (mmHg) 133.75 (122, 144.75)
129.875 (121.69, 
136.38)
0.593
Maternal average diastolic BP (mmHg) 85 (77, 93.5)
83.125 (77.25, 
90)
0.903
1.2.4 Post-randomization (48 – 72hours) vs Postnatal
Factor
Post-randomization 
(48 - 72h)
(n=53)
Postnatal
(n=31)
P 
value
Maternal average (between the 2 readings) 
Right arm systolic BP (mmHg)
131.5 (121.63, 
141.38)
128 
(119.5, 
14.88)
0.713
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Factor
Post-randomization 
(48 - 72h)
(n=53)
Postnatal
(n=31)
P 
value
Maternal average (between the 2 readings) Left 
arm systolic BP (mmHg)
132.5 (122.5, 140.38)
130.5 
(122.5, 
136.5)
0.476
Maternal average (between the 2 readings) 
Right arm diastolic BP (mmHg)
86.5 (78.63, 92)
83 (78.75, 
90.38)
0.707
Maternal average (between the 2 readings) Left 
arm diastolic BP (mmHg)
87.75 (79.38, 93)
84.5 (77, 
91)
0.564
Maternal average (between the 2 readings) 
Right arm MAP (mmHg)
101.175 (92.35, 
108.31)
98.925 
(93.48, 
105.78)
0.745
Maternal average (between the 2 readings) Left 
arm MAP (mmHg)
103.4 (94.6, 109.23)
99.8 
(92.15, 
106.85)
0.953
Maternal HR (bpm) 79.5 (72.5, 84)
87 (70, 
94.5)
0.098
Maternal average systolic BP (mmHg) 131.63 (121.19, 14)
129.88 
(121.69, 
136.38)
0.629
Maternal average diastolic BP (mmHg) 86.375 (80, 92)
83.125 
(77.25, 
90)
0.929
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2. Maternal augmentation index (AIx) and pulse wave velocity (PWV)
2.1 Sildenafil Group
2.1.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre- randomization
(n=32)
Post-
randomization (1 - 
2hour)
(n=35)
P 
value
Aortic AIx (AlxAo) (%) 20 (10.7, 38.2) 14.8 (8.8, 22.1) 0.009
Aortic PWV (m/s) 7.5 (6.4, 8.7) 7.6 (6.6, 9.2) 0.841
AlxAo adjusted for heart rate (%) 29.34 (12.02, 50.08) 17.93 (9.06, 28.73) 0.002
Aortic PWV adjusted for mean 
arterial pressure (m/s)
10.25 (8.76, 11.27) 8.85 (8.04, 10.39) <0.001
2.1.2 Pre-randomization vs Post-randomization (48 – 72hours)
Factor
Pre- randomization
(n=32)
Post-randomization (48 
- 72h)
(n=30)
P 
value
Aortic AIx (AlxAo) (%) 20 (10.7, 38.2) 20.05 (8.45, 30.95) 0.445
Aortic PWV (m/s) 7.6 (6.6, 9.2) 7.85 (6.6, 8.3) 0.221
AlxAo adjusted for heart rate (%) 29.34 (12.02, 50.08) 26.67 (12.41, 45.75) 0.001
Aortic PWV adjusted for mean 
arterial pressure (m/s)
10.25 (8.76, 11.27) 8.59 (7.91, 9.75) 0.016
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2.1.3 Pre-randomization vs Postnatal
Factor
Pre- 
randomization
(n=32)
Postnatal
(n=13)
P 
value
Aortic AIx (AlxAo) (%) 20 (10.7, 38.2)
22.7 (16.13, 
30.68)
0.972
Aortic PWV (m/s) 7.6 (6.6, 9.2) 7.25 (6.1, 8.06) 0.421
AlxAo adjusted for heart rate (%)
29.342 (12.02, 
50.08)
28.25 (14.36, 
44.54)
0.003
Aortic PWV adjusted for mean arterial 
pressure (m/s)
10.25 (8.76, 11.27) 8.30 (7.26, 9.51) 1
2.1.4 Post-randomization (48 - 72H) vs Postnatal
Factor
Post-randomization (48 
- 72h)
(n=30)
Postnatal
(n=13)
P 
value
Aortic AIx (AlxAo) (%) 20.05 (8.45, 30.95)
22.7 (16.13, 
30.68)
0.04
Aortic PWV (m/s) 7.85 (6.6, 8.3) 7.25 (6.1, 8.06) 0.685
AlxAo adjusted for heart rate (%) 26.67 (12.41, 45.75)
28.25 (14.36, 
44.54)
0.706
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Factor
Post-randomization (48 
- 72h)
(n=30)
Postnatal
(n=13)
P 
value
Aortic PWV adjusted for mean 
arterial pressure (m/s)
8.59 (7.91, 9.75) 8.3 (7.26, 9.51) 0.946
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2.2 Placebo Group
2.2.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre- 
randomization
(n=28)
Post-randomization (1 - 
2hour)
(n=32)
P
Aortic AIx (AlxAo) (%)
21.85 (13.48, 
35.73)
19.45 (12.38, 32.5) 0.109
Aortic PWV (m/s) 7.64 (6.3, 9.2) 8 (7.06, 9.5) 0.443
AlxAo adjusted for heart rate (%)
25.66 (17.34, 
47.59)
23.01 (14.76, 40.20) 0.138
Aortic PWV adjusted for mean 
arterial pressure (m/s)
10.70 (8.27, 
12.01)
9.91 (8.70, 11.59) 0.665
2.2.2 Pre-randomization vs Post-randomization (48 – 72hours)
Factor
Pre- 
randomization
(n=28)
Post-randomization (48 
- 72h)
(n=22)
P 
value
Aortic AIx (AlxAo) (%)
21.85 (13.48, 
35.73)
25.4 (13.3, 35.6) 0.042
Aortic PWV (m/s) 8 (7.06, 9.5) 7.75 (7.2, 9.83) 0.91
AlxAo adjusted for heart rate (%) 25.68 (17.34, 27.5 (20.55, 47) 0.52
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Factor
Pre- 
randomization
(n=28)
Post-randomization (48 
- 72h)
(n=22)
P 
value
47.59)
Aortic PWV adjusted for mean 
arterial pressure (m/s)
10.70 (8.27, 
12.01)
10.34 (9.35, 11.41) 0.603
2.2.3 Pre-randomization vs Postnatal
Factor
Pre- 
randomization
(n=28)
Postnatal
(n=13)
P 
value
Aortic AIx (AlxAo) (%)
21.85 (13.48, 
35.73)
25.17 (14.95, 
37.2)
0.195
Aortic PWV (m/s) 7.64 (6.3, 9.2) 7.9 (6.05, 10.75) 0.807
AlxAo adjusted for heart rate (%)
25.66 (17.34, 
47.59)
18.45 (13.59, 
22.36)
0.583
Aortic PWV adjusted for mean arterial 
pressure (m/s)
10.70 (8.27, 12.01)
9.16 (7.01, 
13.22)
1
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2.2.4 Post-randomization (48 – 72hours) vs Postnatal
Factor
Post-randomization (48 
- 72h)
(n=22)
Postnatal
(n=13)
P 
value
Aortic AIx (AlxAo) (%) 25.4 (13.3, 35.6)
25.17 (14.95, 
37.2)
0.734
Aortic PWV (m/s) 7.75 (7.2, 9.83) 7.9 (6.05, 10.75) 0.098
AlxAo adjusted for heart rate (%) 27.5 (20.55, 47)
18.45 (13.59, 
22.36)
0.236
Aortic PWV adjusted for mean 
arterial pressure (m/s)
10.34 (9.35, 11.41)
9.16 (7.01, 
13.22)
0.742
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3. Maternal cardiac function
3.1 Sildenafil Group
3.1.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre-randomization 
(n=44)
Post-randomization (1 
- 2hour)
(n=42)
P 
value
Cardiac Output (CO) (L/min) 6.05 (5.1, 6.93) 6.05 (5, 6.68) 0.703
Cardiac Index (CI) 3.35 (2.9, 3.8) 3.4 (2.9, 3.7) 0.654
Heart Rate (HR) 78 (72, 83.25) 85 (77.25, 92.75) <0.001
Stroke volume (SV) (ml) 75.95 (67.05, 84.83) 66.45 (56.4, 82.94) 0.003
Stroke volume index (SVI) 45 (38, 51.25) 41 (31.5, 47) 0.003
Total peripheral resistance (TPR)
1366 (1209.75, 
1673)
1328.5 (1146.5, 1661) 0.548
Total peripheral resistance index 
(TPRI)
2453 (2153.5, 
3026.5)
2372.5 (2006.5, 2837) 0.457
3.1.2 Pre-randomization vs Post-randomization (48 – 72hours)
Factor
Pre-randomization 
(n=44)
Post-randomization (48 
- 72h)
(n=39)
P 
value
Cardiac Output (CO) (L/min) 6.05 (5.1, 6.93) 6 (5.15, 6.85) 0.718
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Factor
Pre-randomization 
(n=44)
Post-randomization (48 
- 72h)
(n=39)
P 
value
Cardiac Index (CI) 3.35 (2.9, 3.8) 3.4 (3.05, 3.9) 0.566
Heart Rate (HR) 78 (72, 83.25) 83 (72.5, 95) 0.034
Stroke volume (SV) (ml) 75.95 (67.05, 84.83) 74.2 (63.85, 86.65) 0.61
Stroke volume index (SVI) 45 (38, 51.25) 43 (36.5, 46.5) 0.216
Total peripheral resistance 
(TPR)
1366 (1209.75, 1673) 1333 (1118.5, 1611.5) 0.775
Total peripheral resistance 
index (TPRI)
2453 (2153.5, 3026.5) 2302 (1974, 2892) 0.576
3.1.3 Pre-randomization vs Postnatal
Factor
Pre-randomization 
(n=44)
Postnatal
(n=18)
P 
value
Cardiac Output (CO) (L/min) 6.05 (5.1, 6.93) 7 (5.85, 7.75) 0.088
Cardiac Index (CI) 3.35 (2.9, 3.8) 3.85 (3.35, 4.05) 0.093
Heart Rate (HR) 78 (72, 83.25) 87 (81, 94) 0.001
Stroke volume (SV) (ml) 75.95 (67.05, 84.83) 72.75 (62, 89.15) 0.119
Stroke volume index (SVI) 45 (38, 51.25) 42 (34.25, 51) 0.368
Total peripheral resistance (TPR) 1366 (1209.75, 1673) 1248.5 (1084.5, 0.442
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Factor
Pre-randomization 
(n=44)
Postnatal
(n=18)
P 
value
1326)
Total peripheral resistance index 
(TPRI)
2453 (2153.5, 3026.5)
2247 (1964.5, 
2404)
0.347
3.1.4 Post-randomization (48 – 72hours) vs Postnatal
Factor
Post-randomization (48 - 
72h)
(n=39)
Postnatal
(n=18)
P 
value
Cardiac Output (CO) (L/min) 6 (5.15, 6.85) 7 (5.85, 7.75) 0.379
Cardiac Index (CI) 3.4 (3.05, 3.9) 3.85 (3.35, 4.05) 0.49
Heart Rate (HR) 83 (72.5, 95) 87 (81, 94) 0.57
Stroke volume (SV) (ml) 74.2 (63.85, 86.65) 72.75 (62, 89.15) 0.831
Stroke volume index (SVI) 43 (36.5, 46.5) 42 (34.25, 51) 1
Total peripheral resistance 
(TPR)
1333 (1118.5, 1611.5)
1248.5 (1084.5, 
1326)
0.644
Total peripheral resistance 
index (TPRI)
2302 (1974, 2892)
2247 (1964.5, 
2404)
0.644
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3.2 Placebo Group
3.2.1 Pre-randomization vs Post-randomization (1 - 2hour)
Factor
Pre-randomization 
(n=39)
Post-randomization (1 - 
2hour) (n=36)
P 
value
Cardiac Output (CO) 
(L/min)
5.4 (4.8, 6.7) 6 (4.8, 6.9) 0.381
Cardiac Index (CI) 3.1 (2.7, 3.6) 3.3 (2.9, 3.625) 0.202
Heart Rate (HR) 74 (70.5, 88) 78 (73, 85.25) 0.05
Stroke volume (SV) (ml) 69.9 (58.95, 94.85) 69.8 (53.7, 84.2) 0.78
Stroke volume index (SVI) 40 (35, 50) 41 (36, 50) 0.656
Total peripheral resistance 
(TPR)
1516 (1236, 1731.5) 1390 (1119, 1700) 0.42
Total peripheral resistance 
index (TPRI)
2593 (2259, 2956) 2445 (2104, 2894) 0.197
3.2.2 Pre-randomization vs Post-randomization (48 – 72hours)
Factor
Pre-randomization 
(n=39)
Post-randomization (48 
- 72h)
(n=31)
P 
value
Cardiac Output (CO) (L/min) 5.4 (4.8, 6.7) 6 (5.2, 6.6) 0.083
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Factor
Pre-randomization 
(n=39)
Post-randomization (48 
- 72h)
(n=31)
P 
value
Cardiac Index (CI) 3.1 (2.7, 3.6) 3.3 (2.9, 3.85) 0.042
Heart Rate (HR) 74 (70.5, 88) 79 (71, 87) 0.611
Stroke volume (SV) (ml) 69.9 (58.95, 94.85) 75.8 (69.65, 90.15) 0.11
Stroke volume index (SVI) 40 (35, 50) 42.5 (37, 48.5) 0.129
Total peripheral resistance 
(TPR)
1516 (1236, 1731.5) 1410.5 (1228.5, 1760.75) 0.089
Total peripheral resistance 
index (TPRI)
2593 (2259, 2956) 2424 (2136, 3002.5) 0.073
3.2.3 Pre-randomization vs Postnatal
Factor
Pre-randomization 
(n=39)
Postnatal
(n=18)
P 
value
Cardiac Output (CO) (L/min) 5.4 (4.8, 6.7) 7.5 (5.1, 7.7) 0.089
Cardiac Index (CI) 3.1 (2.7, 3.6) 3.85 (3.13, 4.25) 0.068
Heart Rate (HR) 74 (70.5, 88) 89.5 (75.5, 96.75) 0.064
Stroke volume (SV) (ml) 69.9 (58.95, 94.85) 69.8 (50.98, 80.98) 0.369
Stroke volume index (SVI) 40 (35, 50) 42.5 (39, 48.75) 0.896
Total peripheral resistance 1516 (1236, 1731.5) 1215 (1033.5, 0.983
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Factor
Pre-randomization 
(n=39)
Postnatal
(n=18)
P 
value
(TPR) 1689.5)
Total peripheral resistance index 
(TPRI)
2593 (2259, 2956)
2363.5 (1837.5, 
2849.5)
0.966
3.2.4 Post-randomization (48 – 72hours) vs Postnatal
Factor
Post-randomization (48 - 
72h)
(n=31)
Postnatal
(n=18)
P 
value
Cardiac Output (CO) (L/min) 6 (5.2, 6.6) 7.5 (5.1, 7.7) 0.615
Cardiac Index (CI) 3.3 (2.9, 3.85) 3.85 (3.125, 4.25) 0.806
Heart Rate (HR) 79 (71, 87) 89.5 (75.5, 96.75) 0.048
Stroke volume (SV) (ml) 75.8 (69.65, 90.15) 69.8 (50.98, 80.98) 0.03
Stroke volume index (SVI) 42.5 (37, 48.5) 42.5 (39, 48.75) 0.278
Total peripheral resistance 
(TPR)
1410.5 (1228.5, 1760.75)
1215 (1033.5, 
1689.5)
0.903
Total peripheral resistance 
index (TPRI)
2424 (2136, 3002.5)
2363.5 (1837.5, 
2849.5)
0.952
MAP = mean arterial pressure
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Explanation of the Bioreactance technology (NICOM®) (Reproduced from 
https://www.cheetah-medical.com/how-it-works/bioreactance/)
Bioreactance technology measures the phase shift in voltage across the thorax. The human 
thorax can be described in terms of an electric circuit with a capacitor (C) and a resistor (R); 
together these create thoracic impedance (Zo). The two components of impedance are the 
amplitude (a) (the magnitude of impedance, which is measured in Ohms (Ω)) and phase 
(phi, Φ) (the direction of the impedance, measured in degrees). The pulsatile ejection of 
blood from the heart modifies the value of R and C, leading to an instantaneous change in 
the amplitude and phase of Zo. Phase shifts occur due to pulsatile flow, the overwhelming 
majority of which stems from the aorta. Because the volume of thoracic fluid is relatively 
static, the NICOM® signal is unaffected by thoracic fluid status including in cases of 
pulmonary edema. The phase detector within the NICOM® monitor detects the phase shifts 
and computes these into the NICOM® signal.
WHAT IS A PHASE SHIFT?
As the electrical current (AC) voltage and AC current are based on the trigonometric sine 
function, the time delay between the two sine waves in figure 1 can also be represented 
in Phase (or Angle). The orange sine wave begins 0.25 seconds after the blue sine wave. 
Since the duration of a complete sine wave cycle depicted in the image is 1 second, we can 
say that the orange wave began a quarter of a cycle later. Given that a quarter of a cycle of 
a trigonometric Sine function corresponds to 90º, we can say that the orange sine wave is 
phase shifted from the blue sine wave by 90º.
When dealing with sine waves such as AC current and AC voltage, the change is not a 
function of degrees, but is a function of time (in this case in seconds). In the graphic above, 
the X axis is converted to a time axis instead of a phase axis – a sine wave that changes in 
time.
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BUILDING THE SIGNAL FROM PHASE SHIFTS
The signal is generated by the Starling SV and the NICOM® Monitor.
The monitor transmits the AC current to the thoracic cavity via four transmitting sensors and 
detects the phase shifts with an additional four receiving sensors. This signal is Phase based 
and is called the Cheetah signal where each point is a specific phase shift in time. Each 
sample on the Cheetah signal reflects the phase shift detected from the thorax at that time. 
The phase shift detected at any given moment is correlated with cardiac stroke volume.
FROM THE CHEETAH SIGNAL TO STROKE VOLUME
In the figure below the upper graph represents a single “beat” of the Cheetah signal. During 
systole, there is a rapid build up of the phase shifts until a peak is reached in the end of the 
systole. This reflects the increase in aortic blood volume during ventricular ejection. Beyond 
the peak, during diastole there is a decrease in the phase shift representing reduction in 
blood volume. Since flow is defined as a dynamic change in volume, when the Cheetah 
signal is derived by time, the resulting signal represents aortic flow as presented in the lower 
graph which represents a single “beat” of the Cheetah Signal Derivative. Stroke volume is 
found by computing the area under the positive part of the Cheetah Signal Derivative, or the 
part of the waveform that represents systole.
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COMPUTING STROKE VOLUME FROM THE CHEETAH SIGNAL
The maximum flow (dX/dtmax) is measured at the maximum point of the Cheetah signal 
derivative. The Ventricular Ejection Time (VET) is measured from the first zero crossing to 
the second zero crossing. The stroke volume is proportional to the product of dX/dtmax and 
VET which result in an approximation of the main positive area of the Cheetah signal 
derivative. Intuitively, the flow measurement derived by dX/dt is indirectly related to the 
strength of the heart contractility. Greater contractility will induce higher flow and reduced 
contractility produces lower flow.
Once the dX/dt and VET are measured, stroke volume (SV) is obtained as follows
SV = DX/DT × VET
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Bioreactance is a method of processing the impedance signal. It has been suggested that in 
addition to changing resistance to blood flow (Z0), changes in intrathoracic volume also 
produce changes in electrical capacitive and inductive properties which also contribute to the 
phase shifts observed. Bioreactance, which detects relative phase shifts, are therefore 
inherently more robust and less susceptible to the interferences experienced using 
bioimpedance technology. An analogy of this would be the superior sound quality and 
reduced interference of FM (frequency modulation) compared to AM (amplitude modulation) 
radio signals.
Supplementary Figure (NICOM®); a, prewired sensors and bag; b, position of sensors; c, 
Cheetah NICOM monitor. Reproduced from www.cheetah-medical.com
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Supplementary material. 
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